Tarsus Pharmaceuticals Files Current Report
Ticker: TARS · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1819790
| Field | Detail |
|---|---|
| Company | Tarsus Pharmaceuticals, Inc. (TARS) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, sec-filing
Related Tickers: TARS
TL;DR
TARS filed an 8-K on Jan 13, 2025, confirming HQ and Nasdaq listing.
AI Summary
Tarsus Pharmaceuticals, Inc. filed an 8-K on January 13, 2025, to report current information. The filing indicates the company's principal executive offices are located at 15440 Laguna Canyon Road, Suite 160, Irvine, CA 92618. Tarsus Pharmaceuticals' common stock trades on the Nasdaq Global Market under the symbol TARS.
Why It Matters
This 8-K filing serves as a public record of Tarsus Pharmaceuticals' basic corporate information and stock listing details.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain material financial or operational news.
Key Players & Entities
- Tarsus Pharmaceuticals, Inc. (company) — Registrant
- January 13, 2025 (date) — Date of Report
- 15440 Laguna Canyon Road , Suite 160 , Irvine , CA 92618 (address) — Principal executive offices
- TARS (ticker) — Trading Symbol
- The Nasdaq Global Market LLC (company) — Exchange
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report current information as required by the Securities and Exchange Commission, specifically detailing the registrant's name, date of report, and principal executive offices.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on January 13, 2025.
Where are Tarsus Pharmaceuticals, Inc.'s principal executive offices located?
Tarsus Pharmaceuticals, Inc.'s principal executive offices are located at 15440 Laguna Canyon Road, Suite 160, Irvine, CA 92618.
On which exchange is Tarsus Pharmaceuticals, Inc. common stock traded?
Tarsus Pharmaceuticals, Inc. common stock is traded on The Nasdaq Global Market LLC (Nasdaq Global Select Market).
What is the trading symbol for Tarsus Pharmaceuticals, Inc. common stock?
The trading symbol for Tarsus Pharmaceuticals, Inc. common stock is TARS.
Filing Stats: 486 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2025-01-13 08:30:42
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share TARS The Nasdaq
Filing Documents
- d892013d8k.htm (8-K) — 23KB
- d892013dex991.htm (EX-99.1) — 21KB
- g892013ex99_1p10g1.jpg (GRAPHIC) — 389KB
- g892013ex99_1p11g1.jpg (GRAPHIC) — 537KB
- g892013ex99_1p12g1.jpg (GRAPHIC) — 425KB
- g892013ex99_1p13g1.jpg (GRAPHIC) — 304KB
- g892013ex99_1p14g1.jpg (GRAPHIC) — 382KB
- g892013ex99_1p15g1.jpg (GRAPHIC) — 358KB
- g892013ex99_1p16g1.jpg (GRAPHIC) — 264KB
- g892013ex99_1p17g1.jpg (GRAPHIC) — 282KB
- g892013ex99_1p18g1.jpg (GRAPHIC) — 335KB
- g892013ex99_1p19g1.jpg (GRAPHIC) — 296KB
- g892013ex99_1p1g1.jpg (GRAPHIC) — 273KB
- g892013ex99_1p20g1.jpg (GRAPHIC) — 342KB
- g892013ex99_1p21g1.jpg (GRAPHIC) — 330KB
- g892013ex99_1p22g1.jpg (GRAPHIC) — 322KB
- g892013ex99_1p23g1.jpg (GRAPHIC) — 253KB
- g892013ex99_1p2g1.jpg (GRAPHIC) — 573KB
- g892013ex99_1p3g1.jpg (GRAPHIC) — 341KB
- g892013ex99_1p4g1.jpg (GRAPHIC) — 366KB
- g892013ex99_1p5g1.jpg (GRAPHIC) — 171KB
- g892013ex99_1p6g1.jpg (GRAPHIC) — 307KB
- g892013ex99_1p7g1.jpg (GRAPHIC) — 360KB
- g892013ex99_1p8g1.jpg (GRAPHIC) — 424KB
- g892013ex99_1p9g1.jpg (GRAPHIC) — 217KB
- 0001193125-25-005030.txt ( ) — 10987KB
- tars-20250113.xsd (EX-101.SCH) — 3KB
- tars-20250113_lab.xml (EX-101.LAB) — 18KB
- tars-20250113_pre.xml (EX-101.PRE) — 11KB
- d892013d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date:January 13, 2025 Tarsus Pharmaceuticals, Inc. By: /s/ Bryan Wahl Bryan Wahl General Counsel and Corporate Secretary